Role of Oral Bacteria in Mediating Gemcitabine Resistance in Pancreatic Cancer

Role of Oral Bacteria in Mediating Gemcitabine Resistance in Pancreatic Cancer

Oral microbiota have been implicated in pancreatic ductal adenocarcinoma (PDAC) and may contribute to chemotherapy resistance. While previous studies attributed bacteria-induced resistance to indirect host modulation, recent findings suggest a direct mechanism. <i>Escherichia coli</i> ex...

Full description

Saved in:

Bibliographic Details
Main Authors:	Geng Xu, Yaling Jiang, Chen Sun, Bernd W. Brandt, Kamran Nazmi, Luca Morelli, Giulia Lencioni, Elisa Giovannetti, Dongmei Deng
Format:	Article
Language:	English
Published:	MDPI AG 2025-07-01
Series:	Biomolecules
Subjects:	pancreatic cancer gemcitabine cytidine deaminase HPLC drug resistance host microbial interactions
Online Access:	https://www.mdpi.com/2218-273X/15/7/1018
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Improved Antitumor Efficiency of N4-Tetradecyloxycarbonyl Gemcitabine-Loaded Liposomes for Pancreatic Cancer Chemotherapy
by: Wang D, et al.
Published: (2024-12-01)

EXPRESSION OF AID-SPECIFIC mRNA IN PERIPHERAL BLOOD LYMPHOCYTES IN BRONCHIAL ASTHMA
by: V. N. Mineev, et al.
Published: (2015-03-01)

Nab-Paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma: experience of use
by: Elena Ferris Villanueva, et al.
Published: (2015-02-01)

Chlorophyllin exerts synergistic anti-tumor effect with gemcitabine in pancreatic cancer by inducing cuproptosis
by: Jiaqiang Ren, et al.
Published: (2025-04-01)

NCOA6 knockdown enhances RSL3-induced ferroptosis in pancreatic cancer cells and increases the sensitivity to gemcitabine
by: Jia Yuming, et al.
Published: (2025-03-01)

Acute pancreatitis caused by pemetrexed, carboplatin, and gemcitabine in a patient with lung cancer: A rare case report
by: Vishal Kulkarni, et al.
Published: (2019-01-01)

Adjuvant 5‐fluorouracil and portal vein infusion chemotherapy followed by gemcitabine for pancreatic cancer
by: Minoru Kitago, et al.
Published: (2024-07-01)

An exploratory study of INPP4B, a biomarker of gemcitabine chemoresistance in pancreatic cancer
by: REN Jiaqiang, WU Shuai, SU Tong, LI Jie, HAN Liang, WU Zheng
Published: (2024-12-01)

MLN0905 effectively kills gemcitabine-resistant pancreatic cancer cells by targeting PLK1
by: Min Lin, et al.
Published: (2025-07-01)

A research on the mechanism of SERPINA3 promoting malignant progression and gemcitabine resistance of pancreatic cancer by inhibiting ferroptosis
by: HE Yuan, GUO Juncheng, YE Zhibin, WANG Xiaohu, LI Haonan, HUANG Jingbiao
Published: (2025-06-01)

Gemcitabine resistance by CITED4 upregulation via the regulation of BIRC2 expression in pancreatic cancer
by: Eun-Jeong Jeong, et al.
Published: (2025-05-01)

Galectin-3 in tumor-stromal cells enhances gemcitabine resistance in pancreatic adenocarcinoma by suppressing oxidative phosphorylation
by: Yaheng Wu, et al.
Published: (2025-09-01)

A cytidine deaminase-like protein modulates pyrimidine nucleotide homeostasis in Trypanosoma brucei
by: Ana Moro-Bulnes, et al.
Published: (2025-05-01)

Global trends in resistance studies of gemcitabine and pancreatic cancer: a bibliometric and visual analysis from 2010 to 2024
by: Dandan Gu, et al.
Published: (2025-04-01)

ANP32E expression in pancreatic cancer is associated with impaired gemcitabine efficacy and poor patient prognosis
by: Xiaohong Liu, et al.
Published: (2025-08-01)

Cost-effectiveness of NALIRIFOX versus Nab-paclitaxel and gemcitabine in previously untreated metastatic pancreatic ductal adenocarcinoma
by: Wenjie Liu, et al.
Published: (2025-04-01)

TSPAN15 sustains ITGB1 stability to block gemcitabine-induced ferroptosis in pancreatic ductal adenocarcinoma through the FAK/AKT/Mtor-gpx4 cascade
by: Peng Nan, et al.
Published: (2025-09-01)

PLA2G16 expression predicts prognosis and gemcitabine sensitivity in patients with pancreatic cancer
by: Xiaoyu Sun, et al.
Published: (2025-05-01)

Biomimetic cancer cell membrane-enriched vitamin E-stapled gemcitabine-loaded TPGS micelles for pancreatic cancer therapy
by: Miguel Pereira-Silva, et al.
Published: (2025-12-01)

Activation-induced cytidine deaminase in tertiary lymphoid structures: dual roles and implications in cancer prognosis
by: Zhuangwei Lv, et al.
Published: (2025-04-01)

An Imine-Based Two-Dimensional Covalent Organic Framework for Gemcitabine Delivery
by: Kajal Kaliya, et al.
Published: (2025-01-01)

The clinical outcomes of adjuvant gemcitabine plus S-1 in resected pancreatic cancer: a single-center retrospective study
by: Kuan-Yu Tseng, et al.
Published: (2025-07-01)

Single‐molecule methods, activation‐induced cytidine deaminase, and quantum mechanical approach to explore and prevent carcinogenesis
by: Asad Ullah, et al.
Published: (2024-10-01)

A novel nanocarrier based on natural polyphenols enhancing gemcitabine sensitization ability for improved pancreatic cancer therapy efficiency
by: Yuman Dong, et al.
Published: (2025-02-01)

Enhancing chemosensitivity of PANC1 pancreatic cancer cells to gemcitabine using ANGTPL4, Notch1 and NF-κβ1 siRNAs
by: Abdulfattah Al-Kadash, et al.
Published: (2024-12-01)

The functional roles of deoxyelephantopin potential target circTNPO3 in regulating pancreatic cancer malignant phenotype and gemcitabine chemoresistance via miR-188-5p/CDCA3/TRAF2-mediated remodeling of NF-κB signaling pathway
by: Daolin Ji, et al.
Published: (2025-07-01)

Conversion therapy and R0 resection for pancreatic cancer with multiple liver metastases: a case report
by: Sifan Dong, et al.
Published: (2025-07-01)

CircRNAs modulate response of cancer cells to gemcitabine
by: Zahra Tajik, et al.
Published: (2025-12-01)

Gemcitabine: immunomodulatory or immunosuppressive role in the tumor microenvironment
by: Mahnaz Nemati, et al.
Published: (2025-04-01)

Prolonged survival by combination treatment with a standardized herbal extract from Japanese Kampo-medicine (Juzentaihoto) and gemcitabine in an orthotopic transplantation pancreatic cancer model
by: Joanna Napp, et al.
Published: (2024-12-01)

Cost-effectiveness analysis of nimotuzumab combined with gemcitabine for K-Ras wild type locally advanced or metastatic pancreatic cancer in China
by: Rong Long, et al.
Published: (2025-02-01)

The efficacy of gemcitabine and docetaxel chemotherapy for the treatment of relapsed and refractory osteosarcoma: A systematic review and pre‐clinical study
by: Kaan Low, et al.
Published: (2024-09-01)

A glycogen derived from sea urchin-Strongylocentyotus internedius shifts macrophages to the M1 phenotype and enhances the anti-pancreatic cancer activity of gemcitabine
by: Zhenzhen Deng, et al.
Published: (2025-07-01)

Addition of gemcitabine to standard therapy in locally advanced cervical cancer: A randomized comparative study
by: Sanjoy Roy, et al.
Published: (2011-01-01)

Synthesis and properties of magnetically sensitive nanocomposites based on magnetite and gemcitabine
by: A. L. Petranovska, et al.
Published: (2018-11-01)

First case report of neoadjuvant gemcitabine and S-1 for locally advanced unresectable duodenal adenocarcinoma
by: Jiro Kimura, et al.
Published: (2022-05-01)

Fatty acid synthase (FASN) inhibition cooperates with BH3 mimetic drugs to overcome resistance to mitochondrial apoptosis in pancreatic cancer
by: Travis Vander Steen, et al.
Published: (2025-04-01)

PRMT5 Identified as a Viable Target for Combination Therapy in Preclinical Models of Pancreatic Cancer
by: Xiaolong Wei, et al.
Published: (2025-06-01)

Advancing pancreatic cancer therapy by mesothelin-specific nanobody conjugation
by: Soyeon Yi, et al.
Published: (2025-04-01)

ABCG2 protein expression in tumors of patients with non-resectable pancreatic cancer treated with gemcitabine and nab-paclitaxel
by: Susy Shim, et al.
Published: (2025-06-01)